Swedish Orphan Biovitrum Ltd (Sobi™), the Cambridge-based UK affiliate of the international specialty healthcare company Sobi AB, has been rated in first place among companies supplying haemophilia treatments as judged by the IPC Associates’ annual survey 2016 of this market. As a relative newcomer to the haemophilia area, Sobi has been labelled a ‘transparent and trustworthy company’, with patient support groups welcoming its ‘honest and positive’ attitude.
Scoring between ‘very good’ and ‘outstanding’ in 70% of activities, Sobi has made a significant impact in its first full year of commercial haemophilia operations in the UK, building on its existing rare disease experience and applying this within haemophilia. In five of the eight categories, Sobi heads all organisations in the field.
IPC Associates’ independent annual survey compares UK companies who supply fully licensed coagulation products or products on clinical trial or under marketing/clinical investigation. In 2016, twelve suppliers of products to the haemostasis market were included. IPC Associates conduct the survey via personal and confidential interviews with healthcare professionals working in haemophilia treatment centres as well as people working for patient support groups.
Survey respondents commented on Sobi’s high levels of skill, technical knowledge and positive hands-on approach. The company also excelled in the ‘product range’ and ‘quality/safety’ categories, with a near outstanding and actual market leader rating for the ‘state of art’ category. ‘Literature’ and ‘medical/technical support’ scores are already well above ‘average’ for the industry for Sobi’s first year in the rankings.
Paul Cox, Sobi’s Business Unit Director Haemophilia, UK & Ireland, said: “The results of this survey help us believe we’re doing the right thing, and will continue to do so in the future.”